Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy (Q33884484)

28686697

29 July 2017

title

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy (English)

1 reference

head and neck squamous cell carcinoma

29 July 2017

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Gerhard Moser

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Alexander Egle

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

10

Richard Greil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

9

Alexander Gaggl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Thomas Melchardt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Lukas Weiss

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Christof Mittermair

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Daniel Neureiter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Eckhard Klieser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

Simon Gampenrieder

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

7 July 2017

1 reference

29 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

e0180995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

3 June 2020

copyright license

start time

7 July 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Platinum-based chemotherapy plus cetuximab in head and neck cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

5 July 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

MCP-1 and CCR2 gene variants in oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

p53 overexpression impacts on the prognosis of laryngeal squamous cell carcinomas

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5501656

Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma

29 October 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0180995

Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma

21 January 2018

1 reference

12 December 2020

Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial

1 reference

12 December 2020

The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort

1 reference

12 December 2020

Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0180995

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28686697 AND SRC:MED&resulttype=core&format=json

3 June 2020

28686697

1 reference